沃华医药(002107) - 2014 Q1 - 季度财报

Financial Performance - Revenue for Q1 2014 was CNY 71,367,290.16, an increase of 16.60% compared to CNY 61,205,785.66 in the same period last year[9] - Net profit attributable to shareholders was CNY 2,824,133.67, representing a growth of 25.62% from CNY 2,248,189.31 year-on-year[9] - Basic and diluted earnings per share doubled to CNY 0.02 from CNY 0.01, reflecting a 100% increase[9] Cash Flow and Assets - Operating cash flow turned negative at CNY -5,529,911.87, a decrease of 175.96% compared to CNY 7,279,917.30 in the previous year[9] - Total assets at the end of the reporting period were CNY 647,676,066.56, a slight increase of 0.41% from CNY 645,047,401.23 at the end of the previous year[9] Future Expectations - The company expects net profit for the first half of 2014 to range between CNY 298.04 million and CNY 447.06 million, indicating a potential increase of 0% to 50% compared to the same period last year[17] Operating Costs - Operating costs increased by CNY 8,631,500, a rise of 69.15%, primarily due to the implementation of new GMP standards and increased costs related to raw material procurement and quality issues[15] Investment Activities - Investment activities generated a net cash flow of CNY 1,155,270.00, a growth of 96.57% compared to the previous year, mainly due to last year's patent technology purchase[15] Shareholder Information - The company had a total of 22,176 shareholders at the end of the reporting period[11] - The largest shareholder, Beijing Zhongzheng Wanrong Investment Group Co., Ltd., held 50.27% of the shares, totaling 82,427,944 shares[11]